Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) suppresses Lp-PLA2 activity processes for their preparation. Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) also inhibits to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example, atherosclerosis, Alzheimer's disease.

Lp-PLA2-IN-14 (Compound 19), an inhibitor of rhLp-PLA2, exhibits a potent inhibitory effect with a pIC50 value of 8.4. This compound is applicable in research pertaining to neurodegenerative disorders, including Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases such as atherosclerosis [1].

Lp-PLA2-IN-15 (example 2) is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential application in Alzheimer's disease research [1].

Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), formerly known as platelet-activating factor acetylhydrolase (PAF-AH). This enzyme plays a role in the hydrolysis of lipoprotein lipids or phospholipids. The compound holds research potential for neurodegenerative diseases such as Alzheimer's disease (AD), as well as glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases like atherosclerosis[1].

Lp-PLA2-IN-13 (compound 15), a potent Lp-PLA2 inhibitor, holds potential for research in neurodegenerative-related diseases [1].

Lp-PLA2-IN-16 (Example 1) is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential applications in Alzheimer's disease research [1].

Lp-PLA2-IN-12 (compound 19), an Lp-PLA2 inhibitor, is utilized in researching neurodegenerative diseases including Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular conditions such as atherosclerosis [1].

Ergosterol peroxide exhibits anti-cancer, amoebicidal, anticomplementary, antibacterial, antiviral, anti-oxdiant, and anti-melanogenic activities. Ergosterol peroxide could as an anti-atherosclerosis agent, it exhibits hACAT-1 and Lp-PLA2 inhibitory effec